Browse by category

Ascletis Pharma has completed enrolment in its 13-week US Phase II study evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). T2D is the second indication for ASC30, following its first indication of obesity. Topline data from the Phase II study for the treatment of T2D are expected in the third quarter of 2026. The Phase II study is a 13-week, randomised, double-blind, placebo-controlled and multi-cent

The first participants have been dosed in Ascletis Pharma’s US 13-week Phase II study with ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes mellitus. Topline data from the Phase II study are expected in the third quarter of 2026. Ascletis recently completed a 13-week Phase II study evaluating ASC30 for the treatment of obesity in 125 participants with obesity or overweight with at least one weight-related comorbidity at multip

Ascletis Pharma has completed enrolment in its US 13-week Phase IIa study evaluating ASC30, a small molecule oral GLP-1 receptor (GLP-1R)...